Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE-/-) mice. Male streptozotocin (STZ) - induced diabetic ApoE-/- mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE-/- mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E2 and thromboxane B2 (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-α in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE-/- mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Role of Endothelial Dysfunction in Atherosclerosis
Davignon, J., & Ganz, P. (2004) · Circulation · doi:10.1161/01.cir.0000131515.03336.f8 · Cited by 2,513
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets
Drummond, G. R., Selemidis, S., Griendling, K. K., & Sobey, C. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3403 · Cited by 899
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Kawano, H., Motoyama, T., Hirashima, O., Hirai, N., Miyao, Y., Sakamoto, T., Kugiyama, K., Ogawa, H., & Yasue, H. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00168-0 · Cited by 676
Targeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585
Han, J. H., Oh, T. J., Lee, G., Maeng, H. J., Lee, D. H., Kim, K. M., Choi, S. H., Jang, H. C., Lee, H. S., Park, K. S., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4158-2 · Cited by 281
Perivascular adipose tissue: More than just structural support
Szasz, T., & Webb, R. C. (2012) · Clinical Science · doi:10.1042/cs20110151 · Cited by 265
Ojima, A., Matsui, T., Nishino, Y., Nakamura, N., & Yamagishi, S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1395609 · Cited by 223
Cited by
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“Anti-inflammatory n/a Yes [35] Yes [36] Yes [37] No|n/a [38] Figure 1.”
Yang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 280
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
“Empagliflozin reduced the levels of CD68, MCP-1, ICAM-1, TNF-α and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits and thereby ameliorated diabetes-induced endothelial dysfunction [55].”
BackgroundRole of Glucose-Lowering Medications in Erectile Dysfunction
Cignarelli, A., Genchi, V. A., D’Oria, R., Giordano, F., Caruso, I., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112501 · Cited by 30
“In this regard, it has been recently demonstrated that empagliflozin, a selective SGLT2i, not only reduced glucose levels, but also attenuated endothelial dysfunction and atherogenesis and improved cardiac remodelling in diabetic apolipoprotein E–deficient mice and in an experimental model of metabolic syndrome, the o…”
Background
Metadata
- Authors
- Ganbaatar, B., Fukuda, D., Shinohara, M., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., Hirata, K.-I., & Sata, M.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 875
- Pages
- 173040
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W3008379265
- Cited by
- 121
- References
- 11
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.